A lower baseline urinary glucose excretion predicts a better response to the sodium glucose cotransporter 2 inhibitor

You Cheol Hwang, Jae Hyeon Kim, Byung Wan Lee, Woo Je Lee

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine ratio (r=–0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better glucose-lowering efficacy of ipragliflozin.

Original languageEnglish
Pages (from-to)898-905
Number of pages8
JournalDiabetes and Metabolism Journal
Volume43
Issue number6
DOIs
Publication statusPublished - 2019 Dec 1

Bibliographical note

Funding Information:
This study was funded by Astellas Pharma Korea Inc.

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'A lower baseline urinary glucose excretion predicts a better response to the sodium glucose cotransporter 2 inhibitor'. Together they form a unique fingerprint.

Cite this